Sign inJoin waitlistJoin the waitlist

James Cleary

Director, Clinical Research, Division of Gastrointestinal Oncology · Mass General Brigham

Credentials: · · · ·

History

Clinical Research · Mass General Brigham
Present
Mass General Brigham
Present

Dana-Farber Cancer Institute
2006–2008
Internal Medicine
Massachusetts General Hospital
2003–2006
Albert Einstein College of Medicine
1999–2003
Rutgers College
1995–1999

Research

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised,…
The Lancet · 2021 · 2,551 citations
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Nature · 2017 · 1,640 citations
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
New England Journal of Medicine · 2021 · 1,511 citations

Brian Wolpin
38 papers
Geoffrey Shapiro
36 papers
Douglas Rubinson
30 papers
Andrew Aguirre
29 papers
HS
Harshabad Singh
28 papers
Brandon Huffman
22 papers · 16 as a fellow
Kimberly Perez
22 papers
Kimmie Ng
22 papers
Srivatsan Raghavan
17 papers
Jeffrey Meyerhardt
16 papers
Matthew Yurgelun
16 papers
Thomas Abrams
16 papers

Clinical trials

Switch Maintenance in Pancreatic
Principal investigator · Suspended · Phase 1, Phase 2
James Cleary, MD, PhD
2022–2032
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2021–2027
Niraparib in Patients With Pancreatic Cancer
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2018–2026
Pembrolizumab in Metastatic Anal Cancer
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2016–2023